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Abstract  
Background. Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic 
urothelial cancer after failure of platinum-containing therapy. We performed a systematic 
review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety 
of VFL.  
Methods. We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length 
articles providing post-marketing RWD on VFL in patients failing previous chemotherapy 
were eligible. Interventional clinical trials were excluded.  
Results: Ten studies with 797 patients were identified. According to pooled REs analysis, 
overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), 
constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3±4 toxicities were 
neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results 
reported in recent randomized studies. 
Conclusion. Our findings confirm the efficacy and safety of VFL in an unselected population 
and support the use of VFL in the changing treatment paradigm of relapsed mUC. 
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1. Introduction 
  
Urothelial carcinoma (UC) is one of the most common malignancies with an 
incidence of 594,393 new cases per year and a related mortality of 199,922 worldwide [1]. It 
is more commonly found in the urinary bladder, although it can affect all sites of the urinary 
tract. Most UCs present as non-muscle-invasive tumours, which are best treated by surgical 
approaches [2]. However, there is a 10±30% risk of progression to muscle-invasive disease, 
while about 25% of urothelial cancers are muscle-invasive at diagnosis [3]. Muscle invasion 
dramatically changes prognosis, since only around 50% of patients survive 5 years following 
radical local therapy (most commonly radical cystectomy with lymph node dissection or 
radical radiotherapy ) [4]. The major cause of treatment failure and death is the development 
of distant metastases. UC is a chemosensitive cancer and cisplatin-based chemotherapy is 
the current standard of care for metastatic UC [5]. However, most patients will progress after 
first-line chemotherapy [6,7]. Options for second-line treatment are limited and ultimately, the 
majority of patients will die of metastatic chemotherapy-resistant UC [7], although a minority 
of patients may have long-standing responses to novel immunotherapy agents, which have 
been recently introduced in current practice.  
Vinflunine (VFL) is a vinca alkaloid, which binds to tubulin, thus inhibiting microtubule 
polymerization [8]. This leads to reduction of the microtubule network of interphase cells and 
subsequent induction of G2/M arrest in vitro, resulting in apoptosis by mitotic accumulation 
at the metaphase/anaphase transition [9,10]. In addition, anti-angiogenic properties at sub-
therapeutic doses have also been suggested [11]. VFL binding affinity to tubulin is weaker 
than other vinca alkaloids, which probably explains the drug's reduced neurotoxicity [12]. 
Compared with other vinca alkaloids, VFL is a less-potent inductor of drug resistance in vitro 
by yet uncharacterized mechanisms [13]. All together these characteristics suggested a 
possible role of VFL in the systemic treatment of UC [14]. Accordingly, four randomized trials 
investigating VFL alone in second-line therapy, the combination of VFL/gemcitabine as first-
line therapy and VFL as maintenance therapy after first-line showed that VFL was active in 
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all these settings of advanced UC [15±18]. In 2009 VFL was approved as a second-line 
treatment option in metastatic UC (mUC) by the European Medicines Agency (EMA). This 
approval was based on a 2.4-months median overall survival (OS) gain compared with best 
supportive care (BSC) in the per-protocol treated population of a randomized, phase III 
clinical trial [15]. As a consequence all experience with VFL outside the context of clinical 
trials is focused on patients with progression of mUC after first-line chemotherapy. Since the 
approval of VFL, real-world evidence regarding post-marketing use of VFL has been 
published [19±21]. Expectedly, there is considerable variation in the efficacy and toxicity 
data in these reports, but real-world evidence is still important, since patients under study 
conditions may not fully reflect actual clinical practice. In order to effectively synthesize this 
information, we performed a systematic review of all such studies. Our aim was to 
investigate the available international experience on VFL as second-line therapy, and 
through this to evaluate the place of VFL on the developing treatment paradigm of mUC. 
 
2. Methods 
 
This systematic review was performed in accordance with the PRISMA guidelines 
[22]. Eligible articles were identified by a search of the MEDLINE bibliographical database 
for the period from January 1, 2000 to August 31, 2017. The search strategy included the 
following keywords: (urothelial AND vinflunine AND (carcinoma OR carcinomas OR cancer 
OR cancers OR neoplasm OR neoplasms)). Only full-length articles providing post-
marketing, real-world data (RWD) on VFL administration, in patients with mUC failing 
previous chemotherapy, were considered eligible. Interventional clinical trials were excluded. 
Additional inclusion criteria were: English language; at least one of the following endpoints 
should have been reported: overall response rate (ORR), progression-free survival (PFS), 
OS, and toxicity.  
Two investigators, working independently, searched the literature and extracted data 
from each eligible study. In addition, all the references of retrieved articles were checked, in 
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order to identify additional potentially eligible articles. Reviews, case reports and conference 
abstracts were ineligible for this systematic review. In addition, we checked all the 
references of relevant reviews and eligible articles that our search retrieved to identify 
potentially additional eligible abstracts. For each of these studies, the following data were 
collected: first author, year of publication, country of origin, centres (multicentre versus single 
centre), number of patients treated, characteristics of patient population prior to VFL 
utilization, median follow-up, response rate data, median OS in months, median PFS in 
months, and toxicity. When multiple (overlapping) publications stemming from the same 
study were identified, the larger size study was included, unless the reported outcomes were 
mutually exclusive. In an attempt to maximize the strength of this systematic review, we 
contacted the authors of individual studies for clarifications, if necessary. 
 
2.1 Statistical methodology 
 
Lines of therapy were defined by the diagnosis of advanced disease. Therefore, 
patients who received VFL after either neo-adjuvant or adjuvant chemotherapy without any 
previous therapy for advanced disease were considered as first-line patients. ORR was the 
sum of complete and partial response rate (RR), while disease control rate (DCR) was 
defined as the sum of ORR and stable disease. Fixed effect (FE) and random effect (RE) 
models were constructed using inverse variance weighting. For variance stabilization, 
proportions were pooled after Arcsine transformation [23]. Heterogeneity was quantified 
using the I2 measure [24]. The confidence intervals (CIs) are based on exact binomial 
procedures [25]. Forest plots were created to visually demonstrate results. All statistical 
analyses were performed using STATA/SE 15.1 software (©1985±2017; StataCorp LP, 
College Station, Texas, USA). For pooling proportions, the metaprop package was used. 
 
3. Results 
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Search results are shown in Fig. 1. Ten studies [19±21,26±32], totalling 797 patients, 
were included in the analysis (Table 1): one was prospective and nine were retrospective. 
Publication dates ranged from 2014 to 2017. All were post-marketing studies and expectedly 
included patients from 10 European countries and 140 centres. Seven were collaborative 
studies, while three reported single-institution experience.  
 
3.1 Patient demographics 
 
Median age was similar across all studies ranging from 62±69 years. Pooled data for 
baseline characteristics with adequate reporting are shown in Table 2. The respective forest 
plots are included in Fig. S1. Most patients had Eastern Cooperative Oncology Group 
Performance Status (ECOG PS) 1 and a baseline haemoglobin >10 g/dL, while 23% (95% 
CI 19±26) had liver metastases. The pooled baseline characteristics were numerically similar 
to those of the registrational study [15]. 
 
3.2 Utilisation of VFL 
 
All studies reported data on VFL administration and dosing. VFL was administered 
i.v. every 3 weeks, mainly as second-line therapy after platinum failure (Tables 1 and 2); 
however, six studies [20,21,26,27,29,30] also included 72 patients who received VFL beyond 
second-line, while in five studies [20,21,26,27,31] 14 patients had received the drug as first-
line therapy, following failure of perioperative chemotherapy. The impact of administering 
VFL as first-line or beyond second-line in this analysis was, however, minimal (Table 2).  
The median number of VFL cycles was very similar across all studies (3 to 5). In all 
but one study, starting doses were 250, 280 or 320 mg/m2, according to the summary of 
product characteristics [33]. In one study, however, all patients received a suboptimal 
starting dose between 200 and 250 mg/m2 [30]. The percentage of patients starting at 320 
mg/m2 according to pooled REs analysis was 45% (95% CI 31±59), but there was 
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considerable heterogeneity in this respect among the selected studies (Fig. 2). Although the 
reason for starting at a reduced dose was not specified in any of the papers, the percentage 
of patients with ECOG PS t 1 (and history of pelvic radiation, whenever reported) was 
usually sufficient to account for this.  Importantly, 171 patients (21%) received a starting 
dose of d 250 mg/m2, which may be recommended only in case of severe hepatic or renal 
impairment [33]. 
 
3.3 Toxicity 
 
All studies reported on Grade 3-4 toxicities but only six included information for all-
grade toxicities [19±21,26,28,29]. In addition, only six publications included all Grade 3/4 
[21,24±28] and only three all all-grade reported toxicities [21,28,29], while the remaining only 
reported the most frequent. For this reason we only analyzed toxicities reported by at least 
five studies (Table 3, respective forest plots in Fig. 3). We believe that these are the most 
relevant, since they represent the most frequent toxicities also reported by Bellmunt et al. in 
the registrational study [15] (included in Table 3 for descriptive purposes). Specifically for 
nausea/vomiting and asthenia/fatigue, when reported separately, we took into account only 
the most frequent of the two. 
The most prevalent toxicities according to pooled REs analysis including all Common 
Terminology Criteria for Adverse Events (CTCAE) grades were fatigue (41%), constipation 
(39%), nausea/vomiting (25%), anaemia (28%) and neutropenia (25%). The most prevalent 
CTCAE Grade 3±4 adverse events (AEs) were neutropenia (13%), anaemia (9%), fatigue 
(8%) and constipation (7%). As indicated by I2, the level of heterogeneity was higher for all-
grade than for Grade 3-4 toxicities (Fig. 3).  
 
3.4 ORR, PFS and OS 
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All studies reported ORR, PFS and OS. There were few complete responses (n = 23, 3%), 
so our analysis summed all objective responses. Since not all studies reported the number 
of non-evaluable patients, we performed intention-to-treat analyses, i.e. all patients of each 
study were included in the denominator. The pooled ORR with FEs was 18% (95% CI: 15±
21) and with REs was 19% (95% CI 15±23) with an I2 of 42.63%, suggesting moderate 
heterogeneity among the studies analyzed (Fig. 4). The pooled DCR with FEs was 49% 
(95% CI: 46±53) and with REs was 49% (95% CI: 42±55) with an I2 of 66.48% (Fig. S2). 
PFS and OS data from each study are shown in Table 4 and pooled data are depicted in Fig. 
S3. Median PFS ranged from 2.3±6.2 months, while median OS ranged from 5.2±11.9 
months. Median PFS was numerically shorter than that of the registrational study in only one 
study, which included only 16 patients. Median OS was numerically shorter than that of the 
registrational study in only three studies. Two of those included only 16 and 21 patients, 
respectively [31,32].  
 
3.5 Prognostic factors and subgroup analyses 
 
Table 4 depicts subgroup analyses and the prognostic factors associated with OS in 
the five studies which included such analyses. Invariably ECOG PS was associated with 
prognosis. Anaemia and presence of liver metastases were the next most frequent factors 
described. The number of metastatic sites, visceral metastases and administration of >6 
cycles of previous chemotherapy were also found to be favourable prognostic factors in one 
study each. Two studies [21,26] stratified their patients according to the established 
prognostic factors for relapsed mUC, published by Bellmunt et al. [34]. Both confirmed the 
prognostic significance of this algorithm [21,26]. Two other studies used slightly different 
stratification algorithms [20,29]. The first used all previous prognostic factors, adding time-
from-previous-chemotherapy, according to Sonpavde et al. [35], while the other substituted 
number of metastatic sites for Hb d 10 g/dL [29]. 
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4. Discussion 
 
Until recently, VFL represented the only EMA-approved agent for second-line 
treatment of patients with recurrent mUC following first-line platinum-based chemotherapy. 
The approval was based on the results of a phase III trial, which showed a survival 
advantage produced by VFL compared to BSC in the per-protocol-treated population, 
although the primary endpoint of the trial of significant advantage in the intention-to-treat 
population was not met [15]. The US Food and Drugs Association (FDA) did not approve 
VFL, since the median OS of 6.9 months reported in the trial was not particularly convincing 
with regard to the efficacy of this agent. Additionally, toxicity, especially neutropenia and 
constipation, could be of concern regarding the utilization of VFL in everyday practice. For 
this reason, generation of RWD on the efficacy and tolerability of VFL are particularly 
important. RWD provide insights from an environment closer to reality. It has an advantage 
over clinical trial data as it often represents a broader population, often over a longer 
timeframe, and provides information on comparators and outcomes that are not part of the 
clinical trial protocol. Furthermore, real-life data can aid decision makers to better manage 
uncertainty when making reimbursement decisions. Several European series studying the 
utilization of VFL in everyday practice have been published. Understandably, there is 
considerable variation in the baseline characteristics of patients included, the dosing of the 
agent and the outcomes reported. For this reason, a critical review of these publications is 
necessary to extract useful information and reliable conclusions on the everyday utilization of 
VFL. Recently, a meta-analysis including RWD on VFL in mUC was published [36], however, 
this meta-analysis also included all published phase II and III clinical trials of VFL, thus 
neutralizing the important advantages of a pure RWD analysis. We therefore conducted a 
meta-analysis completely focused on RWD on VFL.  
It is reassuring that utilization of VFL was based on the recommended dose and 
schedule in all but one of the included studies. Indicated reductions in starting dose were 
also applied, although adherence to the recommendations in this respect could not be 
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assessed in this study. Furthermore, pooled baseline characteristics were strikingly similar to 
those of the registrational study, while in about 90% of cases, VFL was used as second-line 
therapy after failure of one platinum-based regime. Both these findings suggest that this 
agent was used in patients not heavily pretreated and most likely to benefit, since most 
patients had zero or one risk factors (Table 4). Lack of efficient alternatives at the time of the 
studies analyzed can certainly account to a significant extent for this pattern of practice. 
Importantly, the independent prognostic significance of all factors involved in the Bellmunt 
algorithm [34] was confirmed, while the respective risk stratification was applicable in all four 
studies which reported such analyses, although in two of them risk criteria were slightly 
modified. 
These pooled efficacy data must be interpreted with caution due to the lack of control 
over timing and type of tumour assessments. Nevertheless, it is encouraging that pooled RR 
was comparable to the 16% shown in the registrational study. In most studies, median OS 
was numerically longer than that of the randomized, phase III study of Bellmunt et al. [15]. 
Although this could be due to selection biases, frequently associated with non-comparative, 
retrospective series, it is in line with data derived in recent randomized trials. In these trials 
VFL was compared with two checkpoint inhibitors, namely pembrolizumab and 
atezolizumab, in patients with mUC relapsing after first-line platinum-based chemotherapy 
[37,38] as part of the control arm, which also included taxanes in both cases. 
Pembrolizumab produced an OS benefit over chemotherapy, while atezolizumab did not. 
Median OS for VFL was 7.4 [39] and 8.3 months [38], respectively, both comparing 
favourably with the 6.9 months reported in the first randomized trial [34]. It is interesting that 
data from the IMvigor 211 study [38] showed that the hazard ratio for atezolizumab versus 
VFL was 0.97 compared to 0.73 for atezolizumab versus taxanes. Although not a direct 
comparison between VFL and taxanes, this study shows patients deriving benefits from VFL 
chemotherapy. Therefore, since the approval of VFL, RWD as well as data from clinical trials 
confirming the efficacy of this agent in its indication have emerged.  
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Our review indicates a favourable toxicity profile for VFL. Toxicities reported were 
numerically lower than those reported in the registrational study [15]. This is as expected, 
because toxicity documentation in everyday practice is mainly clinically-driven, which also 
underlines the fact that most toxicities associated with VFL do not result in clinically 
meaningful problems for the patients. Safety data are also influenced by less frequent visit 
procedures compared to those of clinical trials; thus all-grade AEs might be underestimated, 
however, serious events are likely to be reported. This is supported by the fact that the 
variability reported was much higher for all-grade than for the more frequently clinically 
significant Grade 3-4 events, and the frequency of Grade 3-4 events is much closer to those 
reported in the registrational trial. Finally, the lower toxicity could be due to the fact that 
some patients received prophylactic treatment for neutropenia and constipation and the 
initial dose was often reduced based on the conditions and performance of patients. 
The treatment paradigm in the treatment of mUC following failure of first-line platinum-based 
therapy is changing with the introduction of modern immunotherapy, using agents which 
inhibit the interaction between the programmed death-1 (PD-1) receptor on T lymphocytes 
and its ligand (PD-L1). As already mentioned, the PD-1 inhibitor pembrolizumab showed 
superior efficacy over chemotherapy in this setting [37]. Four other checkpoint inhibitors 
(atezolizumab, avelumab, durvalumab and nivolumab) have also been approved for this 
setting. Following these developments, these agents are now considered the standard 
second-line therapy in mUC [40]. Nevertheless, we believe that VFL remains a valid option 
in this setting. Firstly, patients with autoimmune diseases typically cannot receive 
immunotherapy; secondly, most patients treated with immunotherapy will not experience 
long-term benefit, while a small percentage will experience rapid progression [41]. Although 
data on the efficacy of VFL after failure of immune checkpoint inhibition are lacking, this 
agent can be offered to these patients, since no other options are currently available in this 
setting. Furthermore, there are no validated clinical parameters or biomarkers that are 
valuable in selecting which postplatinum mUC patients will benefit mostly from VFL or 
immunotherapy. This represents a significant unmet medical need and an area under 
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intensive research. It is, therefore, important that new clinical trials provide information 
regarding the optimal use of VFL in the new treatment paradigm of mUC.  
In conclusion, three randomized trials, 10 real-world series and two meta-analyses 
(including ours) confirm the efficacy and favourable toxicity profile of VFL in relapsed mUC. 
Efficacy of VFL in everyday practice is comparable to that of reported clinical trials. This 
supports its use in the changing treatment paradigm of this disease. The future role of VFL in 
mUC will be determined by future clinical research in this field. 
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Table 1 
Papers included in the analysis through MEDLINE search. 
Author [ref] Publication 
year 
Country Centres No. of 
patients 
Study type Indication, no. patients (%) 
      First-
line 
Second-
line 
>Second-
line 
Castellano et al. [19] 2014 Spain 15 102 Retrospective  102 (100)  
Retz et al. [20] 2015 Germany 39 77 Prospective 9 (12) 51 (66) 17 (22) 
Pistamaltzian et al. 
[21] 
2016 Greece 7 71 Retrospective 2 (3) 60 (84) 9 (13) 
Médioni et al. [26] 2016 France 22 134 Retrospective 6 (5) 93 (69) 35 (26) 
Holmsten et al. [27] 2016 Sweden/Denmark 3 100 Retrospective 5 (5) 94 (94) 1 (1) 
Hussain et al. [28] 2017 UK/Ireland 9 49 Retrospective  49 (100)  
Passalacqua et al. 
[29] 
2017 Italy 28 217 Retrospective  167 (77) 50 (23) 
Di Lorenzo et al. [30] 2015 Italy 4 10 Retrospective   10 (100) 
Hegele et al. [31] 2014 Germany 8 21 Retrospective 5 (24) 16 (76)  
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Palacka et al. [32] 2014 Slovakia 1 16 Retrospective  16 (100)  
 
  
24 
 
 
Table 2 
Baseline characteristics of 797 patients treated with vinflunine for relapsed urothelial cancer. 
Characteristic No. of 
patients 
No. of 
studies 
I2, 
% 
Fixed effect, % (95% 
CI) 
Random effect, % (95% 
CI) 
Bellmunt et al. [34], 
% 
Sex 669 7 73.4    
 Male    85 (82±88) 83 (78±89) 79 
 Female    15 (12±18) 17 (11±22) 21 
Previous lines of systemic 
therapy 
791 10 95.9   NR 
 0    0 (0±1) 0 (0±3)  
 1    95 (93±96) 90 (76±99)  
 >1    4 (3±6) 8 (1±21)  
ECOG PS 787 9 84.5    
 0    35 (32±38) 38 (29±47) 32 
 1    63 (59±66) 61 (53±69) 68 
Haemoglobin 685 8 90.8    
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 >10 mg/dL    81 (78±84) 73 (63±83) 86 
 <10 mg/dL    19 (16±22) 27 (17±37) 14 
Liver metastases 535 6 0 23 (19±26) 23 (19±26) 29 
 
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NR, not reported. 
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Table 3 
Adverse events of all CTCAE grades and Grade 3±4. 
Adverse event No. of 
patients 
No. of 
studies 
I2 (%) Fixed effect, % (95% 
CI) 
Random effect, % 
(95% CI) 
Bellmunt et al. 
[15], % 
Haematological (all grades)       
 Neutropenia 628 6 95.5 14 (11±16) 25 (12±38) 77 
 Anaemia 526 5 89.4 26 (22±30) 28 (16±40) 93 
 Thrombocytopenia 526 5 63.0 5 (3±7) 7 (3±11) 51 
 Febrile infection 526 5 0 3 (1±4) 3 (1±4) 6 
Non-haematological (all 
grades) 
      
 Constipation 628 6 95.6 33 (29±36) 39 (21±58) 48 
 Asthenia/fatigue 526 5 95.3 34 (30±37) 41 (23±60) 50 
 Nausea/vomiting 494 5 95.6 13 (10±15) 25 (9±42) 29/29 
Haematological (Grade 3±4)       
 Neutropenia 775 10 87.1 6 (5±8) 13 (7±18) 50 
 Anaemia 673 9 77.2 7 (5±9) 9 (5±14) 19 
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 Thrombocytopenia 673 9 0 1 (0±2) 1 (0±2) 6 
 Febrile infection 624 8 64.3 3(1±4) 3 (0±6) 6 
Non-haematological (Grade 3±
4) 
      
 Constipation 775 10 66.3 7 (5±9) 7 (4±12) 16 
 Asthenia/fatigue 673 9 89.3 11 (9±14) 8 (2±17) 19 
 Nausea/vomiting 775 10 24.6 1 (0±3) 1 (0±3) 3/2 
 
CI, confidence interval; CTCAE, Common Terminology Criteria for Adverse Events. 
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Table 4 
Efficacy results of vinflunine treatment in real-world studies in urothelial cancer 
Author [ref] No. of 
patients 
Median 
follow up, 
months 
(95% CI) 
Median PFS, 
months (95% 
CI) 
OS, months (95% CI) Prognostic factors 
    Total PS Haemoglobin Liver No. of risk 
factors (%) 
 
Bellmunt et al. 
[15] 
253 21.5  
(16.7±25.3) 
3  
(2.1±4.0) 
6.9  
(5.7-±8.0) 
 
      0** (25) 
1 (42) 
2 (29) 
3 (4) 
14.2& 
7.3 
3.8 
1.7 
Liver involvement  
No. of organs involved  
Increment of one category 
AST  
Abnormal alkaline 
phosphatase  
Abnormal haemoglobin  
ECOG PS 
Castellano et al. 
[19] 
102 8.9  
(NR) 
3.9  
(2.3±5.5) 
10 
(7.3±12.8) 
0  
t1 
13.2   
6.7 
  No 
Yes 
11.7 
6.1 
  ECOG PS 
Liver metastases 
Médioni et al. [26] 134 17.6  4.2  8.2 0   14.5   >10 9.6 No 9.4 0** (23)  13.2 ECOG PS 
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(15.3±18.8) (2.8±4.8) (6.5±9.4) t1 6.1 d 10 2.4 Yes 5.6 1 (40)  
2 (27) 
3 (10) 
9.9 
3.5 
2.4 
Anaemia 
Liver metastases 
Retz et al. [20] 77 4.6  
(NR) 
NR 7.7 
(4.1±10.4) 
      0Á (16) 
1 (36) 
2 (32)  
t 3 (16) 
18.5 
9.5 
4.1 
2.8 
Liver metastases 
Pistamaltzian et 
al. [21] 
71 11.8  
(6.9±19.4) 
6.2  
(4.4±8.8) 
11.9 
(7.4±21) 
 
0±1  
t 2 
17.6 
4.5 
>10 
d10 
17.3 
4.2 
  0** (18) 
1 (44)  
2 (32) 
3 (6) 
20.5 
17.3 
7.4 
2.4 
ECOG PS 
Anaemia 
Holmsten et al. 
[27] 
100 NR 2.8  
(NR) 
6.3 
(NR) 
 
0±1   
t2 
7 
4.6 
      ECOG PS 
Visceral metastases 
No. of cycles of previous 
chemotherapy 
Hussain et al. [28] 49 9.1 5.1  
(4.3±8.7) 
9.1 
(6.0±12.7) 
         
Passalacqua et 
al. [29] 
217 NR 3.2 (2.6±3.7) 8.1 (6.3±
8.9) 
0 9.7   No 
Yes 
9.5 
8.6 
0$ (29) 
1 (36) 
11 
6.3 
ECOG PS 
No. of metastatic sites 
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2 (26) 
3 (9) 
6.2 
3.1 
Liver metastases 
Di Lorenzo et al. 
[30] 
10 NR 16*  
(10±20) 
32* 
(31±37) 
         
Hegele et al. [31] 21 NR 4.4  
(2.6±6.6) 
6.2 
(3.9±10.7) 
         
Palacka et al. [32] 16 5.2  
(0.6±16.3) 
2.3  
(2.1±3.2) 
5.2 
(3.4±8.8) 
         
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NR, not reported; OS, overall survival; PFS, progression-free 
survival. 
* Weeks. 
 Interquartile range. 
** Risk factors: ECOG PS t 1, liver metastases, Hb d10 g/dL [34]. 
Á Risk factors: ECOG PS t 1, liver metastases, Hb d10 g/dL, time-from-prior-chemotherapy <6 months [36]. 
$ Risk factors: ECOG PS t 1, liver metastases, >1 metastatic site. 
& Risk stratification data from VFL-treated (n = 253) and untreated (n = 117) patients [34]. 
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Figure legends 
 
Fig. 1. Study selection flow chart. 
 
Fig. 2. Forest plot of pooled data on patients starting at 320 mg/m2. ES, estimated size; CI, 
confidence interval. 
 
Fig. 3. Forest plots of pooled data on A) and B) fatigue; C) and D) constipation; E) and F) 
neutropenia. A), C) and E): all-grade toxicities; B), D) and F): Grade 3-4 toxicities. ES, 
estimated size; CI, confidence interval. 
 
Fig. 4. Forest plot of pooled overall response rate data. ES, estimated size; CI, confidence 
interval. 
 
Supplementary Figure legends 
 
Fig. S1. Forest plots of pooled data on A) baseline ECOG PS 0; B) Hb >10 g/dL; C) liver 
metastases. ECOG PS, Eastern Cooperative Oncology Group Performance Status; ES, 
estimated size; CI, confidence interval. 
 
Fig. S2. Forest plot of pooled disease-control rate data. 
 
Fig. S3. Forest plot of pooled overall survival data. 
